Toll Free: +1-888-717-2436


Your Shopping Cart

Contains 0 items
Total: $0.00
View Shopping Cart
Cart Image

customer care
Fax: +1-650-963-2556
Read Frequently Asked Questions

When does GCP Non-compliance at an investigator site compromise a regulatory submission? To File Or Not To File - that is the question!

Buy Now Section

This webinar will help you manage the risks associated with GCP non-compliance at a pivotal investigator site. The training will follow a case-study approach to help you learn how to determine investigator non-compliance and guide you in deciding whether or not to file the efficacy study data in a regulatory application.

Instructor: Stephen Schwartz
Product ID: 702519

Course "When does GCP Non-compliance at an investigator site compromise a regulatory submission? To File Or Not To File - that is the question!" has been pre-approved by RAPS as eligible for up to 1 RAC credits towards a participant's RAC recertification upon full completion.

Why Should You Attend:

GCP Non-compliance at the investigator site remains the sponsor’s primary liability for the rejection of the regulatory application. Fifty percent of all FDA study related investigational site inspections incur some level of GCP noncompliance observations. Most of these GCP non-compliance observations do not result in a rejection of the sponsor regulatory application. Sponsors must be able to make this assessment.

While risk management is a sponsor multi- functional process that begins before the study site is set; there is a single sponsor decision that exposes the sponsor to regulatory consequences beyond simply filing the study data in a regulatory application. The determination of GCP compliance, or the significance of any noted investigator non-compliance, should guide the decision to file the efficacy study data in a regulatory application, or not.

This webinar will include a discussion of two real case studies with significant GCP non-compliance where sponsor regulatory, clinical, and ultimately management decisions were associated with two very different outcomes. One of these companies was the subject of a regulatory agency enforcement action and closed down. The other company successfully brought the study product through an approved NDA.

Areas Covered in the Seminar:

Who Will Benefit:

Instructor Profile:

Steve Schwartz, is the founder of Solaris Research Corporation. He has a background in basic virology research, progressing into 10 years clinical research program administration in the pharmaceutical industry. Entering the CRO industry, he performed clinical monitoring and clinical quality assurance field service using that expertise to achieve a management position at the director level. 10 years of CRO experience culminated in the formation of his full service CRO in 1989, under the initial name of Commonwealth Clinical Research Corporation- now Solaris Research Corp. Steve has also served as the investigator for several phase four clinical trials. He has served on an academic IRB. After a brief retirement he worked as Senior Manager, Global Clinical Operations/ GCP for Reckitt Benckiser Pharmaceuticals from March 2008 until July 2012. The objectives of successfully completing two clinical programs, building a global clinical research function, and developing a novel therapeutic biologic agent were completed in July 2012. Escaping from the corporate environment he is again in retirement he continues to speak and consult internationally to enable the sharing of his experience and expertise in CQA, regulatory affairs, and clinical operations including SOP, TMF, clinical monitoring, best practices.

Relevant to Clinical Quality Assurance, Steve and his associates have designed basic and advanced CQA courses for delivery to Health Canada and US Government agencies, to the pharmaceutical industry, and to academic institutions. Solaris Research provided clinical program management, clinical monitoring, CQA auditing and regulatory consulting. Solaris Research published an electronic clinical trial conduct newsletter from 2000 to 2008.

Steve has a BS degree in microbiology/infectious disease with graduate courses in immunology/virology and pharmacology, and business management. . Steve has made many presentations on clinical operations, clinical monitoring, study program management, and CQA.

Follow us :
Bookmark and Share
Refund Policy
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance.
ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange.

Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time.

If you have any concern about the content of the webinar and not satisfied please contact us at below email or by call mentioning your feedback for resolution of the matter.

We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email or call +1-888-717-2436(Toll Free).

COSO Framework for Internal Controls, Risk Assessment and Financial Statement Audit - 80225SEM

This training hasn't been reviewed yet.

Review this training

Training Options Training Duration = 75 Min
$299.00 Access Recorded Version Only
One Person - Unlimited viewing for 6 Months
(For multiple licenses contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section
$499.00 Get Training CD Only
One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days